Fresh from the biotech pipeline—2017

A positive regulatory environment, combined with a raft of drug approvals that included the first US gene therapy, buoyed the sector in 2017. The FDA's flexibility and focus on marketplace competition is likely to galvanize innovators in the coming year. Chris Morrison reports.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: FDA New drug applications (NDAs) and biologic license approvals 1998–2017.
Figure 2: 2017 Number of FDA-approved NMEs by therapeutic category.
Figure 3: CDER NME approval rates by PDUFA cohort.

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Morrison, C. Fresh from the biotech pipeline—2017. Nat Biotechnol 36, 131–136 (2018). https://doi.org/10.1038/nbt.4068

Download citation

Further reading

Search

Quick links

Sign up for the Nature Briefing newsletter for a daily update on COVID-19 science.
Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing